# Femasys

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/femasys

- Industry: Medical Devices & Equipment
- Headquarters: Suwanee, US
- Website: www.femasys.com
- Total disclosed funding: $8M
- Latest round: Series B (Apr 16, 2015)
- Investors on record: 2

## About

Founded in 2004 and based in Georgia, US, Femasys Inc, is a biomedical firm that develops creative solutions for women all around the world. Kathy Lee-Sepsick is the CEO of the company. In September 2025, Femasys Inc. raised USD 8 million in venture funding from unspecified investors.
The firm's product includes a portfolio of contraception products, fertility products, and biopsy products. Femasys focuses on clinical effects in places that are critically underserved. It delivers minimally invasive, nonsurgical product technologies to women and enhances patient care and overall health economics.  The company’s two lead product candidates offer solutions to improve patient care and health economics: FemBloc, is a non-surgical product for permanent birth control, and FemaSeed, is a directed sperm delivery product for infertility treatment. Femasys’ FemVue product for fallopian tube assessment by ultrasound is marketed in the United States as its commercial priority.

## Funding rounds

- Series B, Apr 16, 2015, $8M — Mario Family Partners, Legacy RHM Capital

## Investors

- Mario Family Partners — Series B
- Legacy RHM Capital (https://capitalatlas.ai/funds/legacy-rhm-capital) — Series B